EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients

Mike Wenzel iD, Lena Theissen, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Benedikt Hoeh, Carolin Siech, Severine Banek, Felix K H Chun, Philipp Mandel

European Journal of Nuclear Medicine and Molecular Imaging · 2025-09 · 52 (11) · 4025-4032

DOI: 10.1007/s00259-025-07256-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 07.04.2025. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Goethe University Hospital, Frankfurt, Frankfurt/Main, Germany. Mike.Wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium, Lutetium, Radioisotopes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Frankfurt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Data on cancer-control outcomes of sequential therapy of Lu- 177-PSMA after radium- 223 are rare.

Methods

Using the Frankfurt Metastatic Cancer database of the Prostate (FRAMCAP) database, we analyzed progression-free (PFS) and overall (OS) survival of patients after radium- 223 pretreatment vs. radium- 223-naïve controls undergoing Lu- 177-PSMA radioligand within 1 st- 7 th line mCRPC treatment.

Results

Of 329 Lu- 177-PSMA mCRPC patients 19% were radium- 223 pretreated, while 81% radium- 223-naïve. The median number of administered mCRPC systemic treatment administrations were significantly higher for radium- 223 pretreated patients (4 vs. 3, p < 0.01). No difference in further baseline or cancer characteristics were observed, similar to PSA response under Lu- 177-PSMA treatment. In PFS analyses, no significant difference between radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients were observed, with median PFS of 16 vs. 12 months (hazard ratio [HR]: 0.73, confidence interval [CI]: 0.52–1.02, p = 0.063). In OS analysis, also no significant differences were observed with median OS of 18 vs. 15 months for radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients (HR: 0.99, CI: 0.71–1.37, p > 0.9). Finally, after additional multivariable adjustment, no differences in PFS and OS outcomes between both groups were observed.

Conclusion

Sequential treatment with radium- 223 prior to Lu- 177-PSMA does not affect PFS or OS outcomes in mCRPC patients. Therefore, this real-world cohort suggests that both radiopharmaceuticals can be administered within mCRPC treatment algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiumLutetiumRadioisotopesHumansMaleAgedTreatment OutcomeMiddle AgedRadiopharmaceuticalsAged, 80 and over

Stichwörter der Autor:innen

Lu- 177MCRPCOSPFSRa- 223Survival

Substanzen

RadiumLutetiumRadioisotopesLutetium-177Radium-223Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology, Goethe University Hospital, Frankfurt, Frankfurt/Main, Germany. Mike.Wenzel@unimedizin-ffm.de.
  • Department of Urology, Goethe University Hospital, Frankfurt, Frankfurt/Main, Germany.
  • Department of Nuclear Medicine, Goethe University Hospital Frankfurt, Frankfurt, Germany.
  • Urologische Klinik München Planegg, Planegg, Germany.
  • Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Mike Wenzel

Förderung

  • Universitätsklinikum Frankfurt

Zitieren

APA

Wenzel, M., Theissen, L., Groener, D., Kriegmair, M., Graefen, M., Maurer, T., Salomon, G., Hoeh, B., Siech, C., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. European Journal of Nuclear Medicine and Molecular Imaging, 52(11), 4025-4032. https://doi.org/10.1007/s00259-025-07256-5

Vancouver

Wenzel M, Theissen L, Groener D, Kriegmair M, Graefen M, Maurer T, et al. Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(11):4025-4032. doi:10.1007/s00259-025-07256-5

BibTeX
@article{Wenzel2025,
  author = {Wenzel, Mike and Theissen, Lena and Groener, Daniel and Kriegmair, Maximilian and Graefen, Markus and Maurer, Tobias and Salomon, Georg and Hoeh, Benedikt and Siech, Carolin and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {11},
  pages = {4025--4032},
  doi = {10.1007/s00259-025-07256-5}
}
Kostenlos starten →